Interleukin-6, but not C-reactive protein, predicts the occurrence of cardiovascular events after drug-eluting stent for unstable angina

Journal of Interventional Cardiology

Volumn 27, Issue 2, 2014, Pages 142-154

  Chen, Shao Liang ^a   Liu, Yan ^a   Lin, Ling ^a   Ye, Fei ^a   Zhang, Jun Jie ^a   Tian, Nai Liang ^a   Zhang, Jun Xia ^a   Hu, Zuo Ying ^a   Xu, Tian ^a   Li, Li ^b   Xu, Bo ^c   Latif, Faisal ^d   Nguyen, Thach ^e  

^a NANJING MEDICAL UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

^c Fuwai Heart Hospital and Cardiovascular Institute   (China)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e St Mary Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR; RAPAMYCIN; ROSUVASTATIN; ZOTAROLIMUS; C-REACTIVE PROTEIN; IL6 PROTEIN, HUMAN; INTERLEUKIN-6;

ADULT; AGED; CONFERENCE PAPER; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS; ANGINA, UNSTABLE; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DEATH; DRUG-ELUTING STENTS; FORECASTING; HUMANS;

AGED; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DEATH; DRUG-ELUTING STENTS; FEMALE; FORECASTING; HUMANS; INTERLEUKIN-6; MALE;

EID: 84897976302     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12103     Document Type: Conference Paper

References (35)

1. Park DW, Seung KB, Kim YH, et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE registry. J Am Coll Cardiol 2010; 56: 117-124.
2. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
3. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. JACC 1999; 34: 1512-1521.
4. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000; 85: 92-95.
5. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992-997.
6. Palmerini T, Marzocchi A, Marrozzini C, et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005; 112: 2332-2338.
7. Fournier JA, Delgado-Pecellín C, Cayuela A, et al. The high-sensitivity C-reactive protein level one month after bare-metal coronary stenting may predict late adverse events. Rev Esp Cardiol 2008; 61: 313-1316.
8. de Winter RJ, Koch KT, van Straalen JP, et al. Creactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003; 115: 85-90.
9. Gach O, Legrand V, Biessaux Y, et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007; 99: 31-35.
10. Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009; 120: 1987-1995.
11. Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug eluting stents. Am J Cardiol 2006; 97: 1311-1316.
12. Choi DH, Park KW, Yang HM, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol 2011; 149: 174-181.
13. Dibra A, Ndrepepa G, Mehilli J, et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 2005; 95: 1238-1240.
14. Niccoli G, Schiavino D, Belloni F, et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. Eur Heart J 2009; 30: 1340-1347.
15. Davignon J., Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 11139-11143.
16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEJM 2008; 359: 2195-2207.
17. Kubota N, Kasai T, Miyauchi K, et al. Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. Heart Vessels 2008; 23: 35-39.
18. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA study. Circulation 2004; 110: 674-678.
19. Niccoli G, Montone RA, Ferrante G, et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010; 56: 1783-1793.
20. Tousoulis D, Papageorgiou N, Stefanadis C., Is C-reactive protein a prognostic marker after angioplasty ? Heart 2009; 95: 957-959.
21. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
22. Hwang SJ, Park KW, Kwon DA, et al. High plasma interleukin-6 is associated with drug-eluting stent thrombosis-possible role of inflammatory cytokines in the development of stent thrombosis from the Korea stent registry. Circ J 2011; 75: 1350-1357.
23. Katsaros KM, Speidl WS, Kastl SP, et al. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 2008; 6: 508-513.
24. Libby P, Ridker PM, Maseri A., Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
25. Rifai N, Ridker PM., Inflammatory markers and coronary heart disease. Curr Opin Lipidol 2002; 13: 383-389.
26. Delhaye C, Maluenda G, Wakabayashi K, et al. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. Am J Cardiol 2010; 105: 826-832.
27. Park DW, Lee CW, Yun SC, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007; 93: 1087-1092.
28. Kang WC, Ahn TH, Moon CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 2009; 95: 970-975.
29. Gibson CM, Karmpaliotis D, Kosmidou I, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006; 97: 1473-1477.
30. Saleh N, Svane B, Jensen J, et al. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. AHJ 2005; 149: 876-882.
31. Yoon SS, Dillon CF, Carroll M, et al. Effects of statins on serum inflammatory markers: The U.S. NHNES 1999-2004. J Atheroscler Thromb 2010; 17: 1176-1182.
32. Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Interv 2010; 3: 90-97.
33. Speidl WS, Katsaros KM, Kastl SP, et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010; 208: 285-289.
34. Sardella G, Mariani P, D'Alessandro M, et al. Early elevation of interleukin-1B and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res 2006; 117: 659-664.
35. Ozer N, Tangurek B, Firat F, et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous intervention. Heart Vessels 2008; 23: 75-82.